Upping Dose May Aid Smoking Cessation After Initial Treatment Failure
By Lori Solomon HealthDay Reporter
TUESDAY, May 7, 2024 -- A dosage increase may provide longer-term benefit for smokers receiving varenicline or combination nicotine replacement therapy who are nonabstinent after six weeks, according to a study published online May 2 in the Journal of the American Medical Association.
Paul M. Cinciripini, Ph.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues evaluated the best subsequent strategy for nonabstinence following initial treatment with varenicline (2 mg/day) or combined nicotine replacement therapy (CNRT; 21-mg patch plus 2-mg lozenge) for six weeks. Nonabstainers were re-randomly assigned to continue, switch treatments, or increase medication dosage for an additional six weeks.
The researchers reported that the end-of-treatment abstinence rate for the 191 phase 1 nonabstainers in the CNRT group was 8 percent for the 90 participants who continued at the dosage condition, 14 percent for the 50 who increased their dosage, and 14 percent for the 51 who switched to varenicline (absolute risk difference [RD], 6 percent), with >99 percent posterior probability that either strategy conferred benefit over continuing the initial dosage. The end-of-treatment abstinence rate for the 157 phase 1 nonabstainers in the varenicline group was 20 percent for the 39 who increased their varenicline dosage, 0 percent for the 41 who switched to CNRT, and 3 percent for the 77 who were assigned to the continued varenicline condition (absolute RD, −3 percent), with >99 percent posterior probability that continuing varenicline at the initial dosage was worse than switching to a higher dosage. Increasing the varenicline dosage had an absolute RD of 18 percent and >99 percent posterior probability of conferring benefit. Only increased dosages of the CNRT and varenicline provided benefit over continuation of the initial treatment dosages for the secondary outcome of continuous abstinence at six months.
"Relative to continuing the same medication, no evidence was found for increased risk of adverse events with the dosage increase for either medication," the authors write.
Varenicline and matching placebo were provided by Pfizer.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
Parental Smoking Possibly Linked to Increased Risk for MS
FRIDAY, July 12, 2024 -- Exposure to parental smoking (ParS) is associated with an increased risk for multiple sclerosis (MS) in later life in certain populations, according to a...
Nicotine Exposure Lower for Children Exposed to Secondhand Vapor
FRIDAY, July 12, 2024 -- Nicotine absorption is much lower in children who are exposed to secondhand vapor versus secondhand smoke, but it is still higher than among those exposed...
Study Looks at Impact of Incentivizing Smoking Cessation in Addition to Usual Care
WEDNESDAY, July 10, 2024 -- Incentivizing smoking cessation increases smoking cessation through 12 weeks, but not at 26 weeks, when missing data are treated as smoking, according...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.